Corcept Therapeutics (CORT) Stock Price, News & Analysis

Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Key Stats

• Today's Range: $69.73 to $71.27
• 50-Day Range: $67.17 to $76.77
• 52-Week Range: $33.34 to $117.33
• Volume: 533,786 shs
• Average Volume: 1.31 million shs
• Market Capitalization: $7.38 billion
• P/E Ratio: 62.03
• Dividend Yield: N/A
• Price Target: $134.50
• Consensus Rating: Buy

Corcept Therapeutics Stock Analysis - MarketRank™

Corcept Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 62nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Corcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Corcept Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 36.03%

Earnings Growth

Earnings for Corcept Therapeutics are expected to grow by 36.03% in the coming year, from $1.36 to $1.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corcept Therapeutics is 62.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.34.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corcept Therapeutics is 62.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.96.

Price to Book Value per Share Ratio

Corcept Therapeutics has a P/B Ratio of 11.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.85% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Corcept Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corcept Therapeutics does not currently pay a dividend.

Dividend Growth

Corcept Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.07

Percentage of Shares Shorted

11.85% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 8.6.

Change versus previous month

Short interest in Corcept Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.38

News Sentiment

Corcept Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Corcept Therapeutics this week, compared to 17 articles on an average week.

Search Interest

11 people have searched for CORT on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,311,201.00 in company stock.

Percentage Held by Insiders

20.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CORT Stock Analysis - Frequently Asked Questions

How have CORT shares performed this year?

Corcept Therapeutics' stock was trading at $50.39 at the start of the year. Since then, CORT stock has increased by 39.6% and is now trading at $70.36.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings data on Thursday, July, 31st. The biotechnology company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm's revenue was up 18.7% on a year-over-year basis.
Read the conference call transcript.

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' top institutional shareholders include Ingalls & Snyder LLC (7.28%), Parallel Advisors LLC (3.65%), State Street Corp (2.82%) and Geode Capital Management LLC (1.82%). Insiders that own company stock include Joseph K Belanoff, Hazel Hunt, Gary Charles Robb, Joseph Douglas Lyon, Sean Maduck, William Guyer, David L Mahoney and Daniel N Swisher, Jr.
View institutional ownership trends.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CORT
• CIK: 1088856
• Web: www.corcept.com
• Phone: (650) 327-3270
• Fax: 650-327-3218
• Employees: 300
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Corcept Therapeutics: $134.50
• High Price Target: $145.00
• Low Price Target: $121.00
• Potential Upside/Downside: +91.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.13
• Trailing P/E Ratio: 62.24
• Forward P/E Ratio: 51.71
• P/E Growth: N/A
• Net Income: $141.21 million
• Net Margins: 18.51%
• Pretax Margin: 17.63%
• Return on Equity: 20.10%
• Return on Assets: 16.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.06
• Quick Ratio: 2.98

Sales & Book Value

• Annual Sales: $716.08 million
• Price / Sales: 10.35
• Cash Flow: $1.24 per share
• Price / Cash Flow: 56.68
• Book Value: $6.03 per share
• Price / Book: 11.66

Miscellaneous

• Outstanding Shares: 105,372,000
• Free Float: 83,455,000
• Market Cap: $7.41 billion
• Optionable: Optionable
• Beta: 0.20